focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Arun Sanyal appointed to Scientific Advisory Board

14 Mar 2017 07:00

RNS Number : 3208Z
Tiziana Life Sciences PLC
14 March 2017
 

Tiziana Life Sciences PLC

 

("Tiziana" or the "Company")

 

 

Tiziana Life Sciences Appoints Dr. Arun Sanyal to its Scientific Advisory Board

 

Dr. Arun Sanyal is a distinguished professor and a key opinion leader in liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)

 

London, 14 March 2017 - Tiziana Life Sciences plc (AIM: TILS, the "Company"), a clinical stage biotechnology company developing targeted drugs for cancer, autoimmune and inflammatory diseases, announces the appointment of Dr. Arun Sanyal as a new member of its Scientific Advisory Board.

 

Gabriele Cerrone, Executive Chairman of the Company commented: "We are absolutely delighted to welcome Professor Sanyal as a distinguished new member of Tiziana's Scientific Advisory Board. His esteemed medical career covering liver cirrhosis, non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) is a strategic addition to our team for further clinical development of NI-0401, a fully human anti-CD3 mAb for treatment of NASH and primary biliary cholangitis (PBC).

 

"Oral treatment with non-Fc binding anti-CD3 mAb with exceptional tolerability is an innovative approach for the treatment of liver inflammatory diseases such as NASH and NAFLD. I am pleased and excited to be a part of the team for clinical development of NI-0401", said Professor Sanyal.

 

About Professor Arun Sanyal

 

Arun Sanyal, MD is the Professor of Medicine, Physiology and Molecular Pathology, Division of Gastroenterology, Hepatology and Nutrition at the Virginia Commonwealth University (VCU) School of Medicine. Dr. Sanyal is special Council Board Member of NIAAA (National Institute on Alcohol Abuse and Alcoholism) and has been a past President of the AASLD (American Association for the Study of Liver Diseases). He has chaired committees at the NIDDK NASH clinical research network and the NIH hepatobiliary study section. Dr. Sanyal was instrumental in establishing the international Liver Forum for NASH and continues to serve as a Chair of this organization comprising industry, academia and regulatory bodies from the USA and EU. Dr. Sanyal is also leading several major drug trials for the treatment of NASH. He has published over 300 papers in leading medical journals and periodicals throughout his career.

 

About Tiziana Life Sciences

 

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology.

 

The Company is focused on its lead compound, milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division as well as a number of other protein kinases. Milciclib is currently completing phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy and has filed an IND to enroll patients in an exploratory trial in Hepatic Cellular Carcinoma (HCC).

 

The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered anti-human CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

 

Tiziana Life Sciences' clinical development teams are working on its Bcl-3 candidate; which has a prominent role in the metastasis of mammary cancers, and has elucidated the mechanism of Bcl-3 action to be a regulator of cancer cell motility and has also determined that Bcl-3 inhibition suppresses cell motility in triple-negative, HER-2-positive PR- and ER-positive breast cancer sub-types, suggesting that Bcl-3 may be a master regulator of this metastatic property not only in aggressive breast cancers, but across the clinical spectrum of breast disease. The Company is preparing the IND package with the intention of progressing to clinical trials early 2017.

 

For more information go to http://www.tizianalifesciences.com

 

 

Contacts

 

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder

 

+44 (0)20 7493 2853

Cairn Financial Advisers LLP (Nominated adviser)

Liam Murray

 

+44 (0)20 7213 0880

Beaufort Securities Limited (Broker)

Elliot Hance

 

+44 (0)20 7382 8300

FTI Consulting

Simon Conway / Natalie Garland-Collins

+44 (0)20 3727 1000

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAJJMFTMBABBPR
Date   Source Headline
8th Apr 20097:00 amRNSIssue of Equity
31st Mar 200910:49 amRNSTotal Voting Rights
26th Mar 20095:38 pmRNSNotification of Major Interest in Shares
26th Mar 200912:49 pmRNSResults of General Meeting
25th Mar 20099:30 amRNSNotification of Major Interest in Shares
25th Mar 20097:00 amRNSManufacturing Agreement
25th Mar 20097:00 amRNSDistribution Agreement and Issue of Equity
12th Mar 20097:00 amRNSFirst stage peptide studies
4th Mar 20094:07 pmRNSHolding(s) in Company
2nd Mar 20097:00 amRNSEGM Circular
27th Feb 20093:09 pmRNSTotal Voting Rights
26th Feb 20097:00 amRNSHoldings in Company
19th Feb 20097:00 amRNSFurther issue of shares
18th Feb 20097:00 amRNSIssue of Equity and Shareholdings
30th Jan 200912:53 pmRNSTotal Voting Rights
26th Jan 200912:21 pmRNSDistribution agreement in Turkey
20th Jan 20095:03 pmRNSHolding(s) in Company
15th Jan 20091:43 pmRNSIssue of Equity
6th Jan 20093:23 pmRNSResults of General Meeting
5th Jan 20094:41 pmRNSIssue of Equity
31st Dec 20087:00 amRNSTotal Voting Rights
19th Dec 20084:22 pmRNSHolding(s) in Company
12th Dec 200810:47 amRNSNotice of EGM
9th Dec 20084:30 pmRNSIssue of Equity
8th Dec 200811:15 amRNSA Book on Zolpidem Effects Published
4th Dec 200810:13 amRNSFull Colostrinin Study Results published
28th Nov 20084:24 pmRNSTotal Voting Rights
26th Nov 20087:00 amRNSColostrinin Test marketing in Poland
25th Nov 20083:39 pmRNSIssue of Equity
24th Nov 20087:00 amRNSFocus on Colostrinin revenue generation
10th Nov 20087:00 amRNSIssue of Shares
4th Nov 20081:10 pmRNSShareholding
31st Oct 200810:56 amRNSTotal Voting Rights
27th Oct 20087:00 amRNSIssue of Equity
13th Oct 20085:19 pmRNSSignificant Shareholding
9th Oct 20083:59 pmRNSHolding(s) in Company
9th Oct 20087:00 amRNSEuropean Launch of Colostrinin in Cyprus
6th Oct 200812:51 pmRNSGeneral Meeting, Share Capital Sub-division
6th Oct 20087:00 amRNSZolpidem Review
2nd Oct 20082:03 pmRNSSignificant Shareholding
30th Sep 20083:44 pmRNSTotal Voting Rights
23rd Sep 20085:29 pmRNSHolding(s) in Company
23rd Sep 20085:21 pmRNSHolding(s) in Company
23rd Sep 20087:00 amRNSInterim Results
15th Sep 20087:00 amRNSIssue of Equity
12th Sep 20087:00 amRNSGeneral Meeting
2nd Sep 20084:07 pmRNSTR-1 announcement
29th Aug 200812:33 pmRNSTotal Voting Rights
13th Aug 20087:00 amRNSPlacing
12th Aug 20087:00 amRNSFinancing and Commercial Upda

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.